


INVITATION

LAI Pharmacokinetics: An Enlightened Approached to Maintaining Recovery



Date & Time: Thursday 27th October 2022 from 6.30 PM



Venue: Hilton Hotel Surfers Paradise
“The New Refurbished Promenade Room”
6 Orchid Avenue, Surfers Paradise 4217

Please join us for a multidisciplinary team dinner meeting designed for Health Care Professional. This meeting aims to be informative and interactive. Nga will go through the unique properties and pharmacokinetic profiles of different long-acting antipsychotics, prescribing considerations, reconstitution and administration. Also, its' pivotal role in efficacy and side effects. This will allow clinicians to make informed decisions about how best to manage patient's care and optimized treatment concordance to the Recovery Model.



Speaker:

Nga Tran

Consultant & Lead Mental Health
Pharmacist
St Vincent's Melbourne



Chair:

Dr Emmily Bueno De Mesquita

Consultant Psychiatrist Gold Coast
University Mental Health &
Specialist Services



Co-Chair:

Jason Keily

Senior Pharmacist
Greg Keily Chemist,
Gold Coast

Agenda

Registration: 6.30PM

Dinner: 7:00 PM

Presentation: 7:00 PM

Q&A: 8.30 PM

Close: 9:00 PM



October 21st, 2022

Please RSVP to Product Specialists
below & with any Dietary
Requirements



Nancy Granata

Neuroscience

Mobile: 0477 560 551

Email: NGranata@its.jnj.com

Paul Keighley

Mood Neuroscience

Mobile: 0482 907 792

Email: Pkeighle@its.jnj.com

Speaker Bio:

Nga is a consultant Pharmacist and the Lead Mental Health Pharmacist/ Pharmacist In-Charge at St Vincent's Mental Health – Melbourne (SVMH).

She has been granted the Honorary Fellow at Department of Psychiatry – The University of Melbourne since 2009. Since 1997 Nga has been involved in a significant number of projects aimed at enhancing medication adherence including:

- The development of the 2010 post graduate Mental Health Online course for pharmacists – Monash University
- *Contributing to the revised TG-Psychotropic version 7th and the RANZCP 2013 Clinical Practice Guideline – Schizophrenia and Related Disorders.*
- Co-author of the 'Psychiatric medication information – A Guide for Patients & Carers' booklet (co-author with Professor David Castle). This publication has also been translated into Vietnamese, Chinese, Greek, Italian, Arabic and Malay; and to date around >80,000 copies have been distributed throughout Australia and overseas. An online version is also available from various mental health websites.
- She is also the project manager of www.asmile.org.au: one-stop-shop web-based mental health information for consumers, carers and mental health clinicians.

Her LAI project commenced in June 2018 when Nga was involved with the SVMH - 5th year medical student QA – LAI project, which subsequently provided Nga with an opportunity to refine the delivery of LAIs, particular the second generation LAIs at SVMH

This scientific program is supported and funded by Janssen-Cilag Pty Limited (Janssen) and is intended for educational purposes and for healthcare professionals only. The opinions and views expressed in this program are those of the presenters and do not constitute the opinions or recommendations of Janssen or any of its employees. This information is not medical advice and no decision relating to the management of any patient should be made with reliance on the information contained in this program. It is your responsibility to prescribe appropriate treatments in accordance with your clinical judgment and by reference to the appropriate information supplied with the relevant product, including in relation to any indication, dosage, route of administration. By joining this program, you accept your obligation to maintain confidentiality of all presentations made during the program and you accept that you are not authorised to record, reproduce (take screenshots), distribute, communicate publicly or transform any content of presentations made during this program. This program may contain information on products or indications currently under investigation and/or that have not been approved by the regulatory authorities. Information included in these slides may contain reference to compounds in development and/or unlicensed indications. Please refer to the relevant Prescribing Information of any compounds mentioned in this webcast for full prescribing information. As Prescribing Information may vary from country to country, please refer to your local Prescribing Information for complete details.

Janssen-Cilag Pty Ltd. ABN 47 000 129 975. 1-5 Khartoum Rd, Macquarie Park NSW 2113. Ph: 1800 226 334. CP-303637. SSW. JAN-003068-00. Date of preparation: March 2022.